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somatic mtDNA mutations
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Hushan Yang5 and Jinliang Xing1*

Abstract
Background: Previous studies have indicated that tumor mitochondrial DNA (mtDNA) mutations are primarily
shaped by relaxed negative selection, which is contradictory to the critical roles of mtDNA mutations in
tumorigenesis. Therefore, we hypothesized that site-specific selection may influence tumor mtDNA mutations.
Methods: To test our hypothesis, we developed the largest collection of tumor mtDNA mutations to date and
evaluated how natural selection shaped mtDNA mutation patterns.
Results: Our data demonstrated that both positive and negative selections acted on specific positions or functional
units of tumor mtDNAs, although the landscape of these mutations was consistent with the relaxation of negative
selection. In particular, mutation rate (mutation number in a region/region bp length) in complex V and tRNA
coding regions, especially in ATP8 within complex V and in loop and variable regions within tRNA, were
significantly lower than those in other regions. While the mutation rate of most codons and amino acids were
consistent with the expectation under neutrality, several codons and amino acids had significantly different rates.
Moreover, the mutations under selection were enriched for changes that are predicted to be deleterious, further
supporting the evolutionary constraints on these regions.
Conclusion: These results indicate the existence of site-specific selection and imply the important role of the
mtDNA mutations at some specific sites in tumor development.

Background
The human mitochondrial genome is an about 16.5kbp
circular mitochondrial DNA (mtDNA) that harbors a control region of 1.1kbp and 37 genes that encode 2 rRNA,
22 tRNA, and 13 proteins of oxidative phosphorylation.
Among them, 7 genes encode subunits of complex I
(ND1–6 and ND4L); 1 gene encodes a subunit of complex
III (CYTB); 3 genes encode subunits of complex IV
(COX1–3); and 2 genes encode subunits of complex V
(ATP6 and ATP8) [1]. Due to the lack of protective
histones and efficient DNA repair system, the mutation
frequency of mtDNA is about 10 times higher than that of
nuclear DNA [2]. In the past decade, high-frequency
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somatic mtDNA mutations have been reported in a
variety of diseases, especially in cancers [3, 4].
A series of previous studies established a connection
between mitochondrial dysfunctions caused by mtDNA
mutations and tumor development and metastasis [5–10].
For example, Cruz-Bermúdez et al. showed that cybrids containing mutations in ND1 (m.3460G > A), ND4
(m.11778G > A) and ND6 (m.14484 T > C) of mtDNA
exhibit the enhanced tumorigenicity [5]; Ishikawa et al.
revealed that the G13997A and 13885insC mutations in the
coding region of ND6 gene confer an increased metastatic
potential in mouse P29 cell line that originated from Lewis
lung carcinoma [6].
On the other hand, however, a handful of studies indicated that mtDNA mutations in tumors are primarily
shaped by the relaxation of negative selection relative to
germline, rather than positive selection [11–13]. For
example, Coller et al. reported that random processes are
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sufficient to explain the incidence of homoplasmic mtDNA
mutations in human tumors without the need of positive
selection pressure [11]. Stafford et al. concluded that the relaxation of negative selection shapes mtDNA mutation
landscapes in cancer cells, as evidenced by the higher ratio
of nonsynonymous to synonymous mutations among these
mutations [12]. Michele Vidone et al. extracted mtDNA
reads from WGS and WES data of glioblastoma multiforme
with MToolBox [14] and found that the large majority of
mtDNA mutations does not pass the prioritization filters
and only a relatively limited burden of pathogenic mutations, which did not appear to determine a general impairment of the respiratory chain, is indeed carried by GBM
[15]. Consistently, Liu et al. [13] reported that mtDNA
mutations in esophageal cancer and other tumors are most
likely shaped by the relaxation of negative selection, and
pointed out that the observation of some level of positive
selections [16] is likely due to sample mix-up or contamination of exogenous DNA. Recently, two groups [17, 18]
reported that most of missense mutations of mtDNA do not
have distinct physiological advantages, indicating that these
mutations are not under positive selection. In addition, several studies also concluded that mtDNA mutations are
not related to the developments of most cases of lung cancer [19] and head and neck squamous cell carcinoma [20].
All of these lines of evidence seem to be contradictory to
the critical roles of mtDNA mutations in tumor development, leaving unclear whether somatic mtDNA mutations
are drivers, or just bystanders, of tumor development.
The discrepancies among the findings of these various
studies may partially be attributed to their limitations, such
as small patient populations, incapacity of sequencing
methods to detect low level of heteroplasmy, and neglect of
replication-mediated mutation frequency bias. Another possibility is that these evolution studies have mainly focused on
the overall level of mtDNA mutations, but not on their level
in specific regions or individual positions. In contrast, functional studies have mostly focused on individual mutations.
To shed more light on the subject, we aimed to explore
whether site-specific natural selection might affect tumor
somatic mtDNA mutations and, more importantly, their
functions. We performed a systematic and comprehensive
exploration of mtDNA mutations in various cancer types,
and we developed the largest collection of mtDNA
mutations in cancer to date using next generation sequencing (NGS) data generated in various sources, including
The Cancer Genome Atlas (TCGA), International Cancer
Genome Consortium (ICGC), other publications, as well as
our own lab. We analyzed the mutations across the mitochondrion genome as well as in different genomic regions
and functional units (e.g., gene domains, codons, amino
acids) to evaluate how natural selection shapes mtDNA
mutation patterns both globally and locally. These comprehensive analyses of mtDNA mutations, conducted at an
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unprecedented scale, shed important novel insights on the
roles of mtDNA mutations in tumorigenesis.

Methods
Data of somatic tumor mtDNA mutations from public
resources and our lab

We identified 5423 somatic mtDNA mutations from
whole genome sequencing (WGS) and whole exome sequencing (WES) data reported in literature [17, 18, 21], as
well as in TCGA (https://portal.gdc.cancer.gov/exploration?searchTableTab=mutations&ssmsTable_size=100) and
ICGC (https://dcc.icgc.org/repositories) datasets. For patients who were present in two or more datasets and
sequenced by the same method (WES or WGS), the mutations were intersected; for patients who were present in
two or more datasets and sequenced by different methods,
the data from WGS were retained. Seven patients with an
extremely large number of somatic mutations (≥13) were
excluded from further analyses.
In addition, we used mtDNA capture sequencing
approach to identify 104 somatic mutations from 54 colon
cancer patients, 357 somatic mutations from 143 hepatocellular carcinoma (HCC) patients, and 36 somatic
mutations from 15 kidney cancer patients. All these mutations derived from tumor tissue in our lab were verified by
parallel sequencing of the non-tumor tissue of the same
patient. Considering the error rate of the Illumina sequencing platform, only the somatic mutations with ≥2% of
variant allele fractions were counted.
Finally, we generated a combined dataset containing 26
tumor types, 3277 patients, and 5920 mutations, the most
comprehensive tumor mtDNA mutation dataset to date
(Additional file 1: Table S1 and Additional file 2: Table S2).
Among them, there were 2465 mutation records with
heteroplasmic level data from three publications. The
heteroplasmic levels of 497 mutations from our lab data
were calculated as the ratio of the mutant reads in all reads
that cover the mutation positions. All mutations were
annotated using Annovar software [22].
Germline variation data in natural human population

Germline variation data containing 4322 mtDNA single
base substitutions in the natural human population was extracted from phylotree (Build 17, 18 Feb 2016) [23]. The
htm file of mtDNA tree Build 17 containing all mtDNA variations among populations to date was downloaded (http://
www.phylotree.org/builds/mtDNA_tree_Build_17.zip) and
the base substitution information was extracted using a
homemade python script. (Additional file 3: Table S3).
Recurrent rate analysis

Recurrent rate of mutation in a specific region was
determined by formula:
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F ¼ ΣR
L , in which F stands for mutation rate, R for
recurrent times of mutations in a position, and L for the
length (bp) of regions. If the R value of a mutation was
greater than 1 in patient group, this mutation was
considered recurrent mutation.
Prediction of functional impacts of mutations in mRNA
and tRNA coding regions

The functional impacts of mutations in mRNA coding
regions were predicted according to Mitimpact 2.5 [24],
and were classified as high, medium, low, or neutral impact.
The functional impacts of mutations in tRNA coding
regions were predicted, as described by Kondrashov et al.
[18], and were classified as either benign or deleterious.
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related variables. All p-values were two-tailed. Residual
was calculated by the difference between simulated data and
observed data of a mutant codon or an amino acid. Stan
dardized residual was calculated by formula: δ ¼ δ−δ =σ,
in which δ* stands for standardized residual, δ for residual of
a certain data point, δ for the average of all residuals, and σ
for the standard deviation of all residuals. Standardized
residuals greater than 2 were considered significant deviation
of observed values from simulated values.
Ethical statement

The study was approved by the Institutional Review
Boards of FMMU and informed written consent was
obtained from each patient. The experiment was
conducted according to the Declaration of Helsinki.

Simulation of mtDNA mutations

We now describe a process to simulate mtDNA mutations
under neutrality as a reference. Since it is impossible to
know the mutation rate of each base under neutrality, we
assumed that the vast majority of the mtDNA mutations in
tumors were derived under neutrality, and selection plays a
negligible role in shaping the overall mutation pattern.
Under this assumption, we utilized the mutations in the
large-scale dataset we collected to calibrate neutral mutation
rates. Specially, we calculated mutation frequency of each of
the possible nucleotide base substitutions (12 types in total)
based on the observed base substitutions in this dataset.
That is, for each of the 12 base substitutions, we counted
the number of occurrences observed in this dataset, to represent the mutant frequency under neutrality; such estimates are expected to be robust given the large size of the
collected mutation dataset. In simulating a mutation dataset
under neutrality, we first stored all the calibrated base substitution frequencies in a file (Additional file 4: Table S4),
and then used a homemade python script to randomly
simulate 12 types of base substitutions, according to the
mutation frequencies stored in this file (Fig. 1b). The data
thus simulated have the same distribution of mutations
observed in the large-scale mutation dataset we collected,
representing mutations derived under neutrality. We
repeated this process N times to generate random replicates
of mutations, and used the simulated datasets as a reference
of neutrality to compare against the observed mutations in a
dataset. Simulating scripts are available from https://github.com/gadbee/Bioinformatics.
Statistical analysis

All statistical tests were performed using Graphpad
Prism software (GraphPad Software, Inc.). Comparisons
between groups with continuous variables and categorical variables were performed using Student’s t test, and
then ANOVA and Chi Square test. Pearson’s correlation
coefficient was used to evaluate the correlations among

Results
Characteristics of 5920 Single Base mtDNA mutations

A total of 5920 single base mutations from 3277 patients of
26 tumor types (Additional file 1: Figure S1) were collected
from two databases (TCGA and ICGC), three previous
publications, and our mtDNA sequencing data (see
Materials and Methods and Additional file 2: Table S2).
Similar to previous report [17], a high consistency among
WGS, WES, and mtDNA capture data was observed by
comparing the proportion of synonymous and nonsynonymous mutations (Additional file 1: Figure S1B). In
addition, we also analyzed the correlation of base substitution numbers or the amino acid substitution number
between WGS and WES data (Additional file 1: Figure
S1C, D) or between WGS + WES and mtDNA capture data
(Additional file 1: Figure S1E, F) and found a high
consistency of substitution pattern among the data derived
from different sequencing methods. These findings indicated that all data were correctly combined for further analyses. A total of 5920 mutations included 816 synonymous,
2946 nonsynonymous, and 209 stop-gain/stop-loss mutations at mRNA coding regions and 1949 mutations at
tRNA, rRNA coding regions and non-coding region. The
vast majority (5449, 92.04%) were transitions (Fig. 1a), and
most (5447, 92.01%) mutations were located in coding regions (Fig. 1a). The mutations had an obvious bias towards
specific base substitutions, with CH > TH followed by TL >
CL having a much higher rate than others (Fig. 1b).
Among the 3277 tumors that harbored at least one
somatic mutation, 1500 (45.77%) had multiple mutations,
ranging from 2 to 8 (Fig. 1c). The mutation rate (mutation
number in a region/region bp length) in non-coding regions
were significantly higher than those in coding regions (Fig.
1d). The average mutation number per patient in different
tumor types was 1.82, ranging from 2.29 (bile duct cancer)
to 1.22 (central nervous system tumors) (Fig. 1e, left). Interestingly, the average mutation number in sarcomas was
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Fig. 1 Characteristics of 5920 tumor somatic mtDNA single base mutations. a Number and proportion of mutations in different regions. b
Number and proportion of nonsynonymous mutations, synonymous mutations, stoploss mutations and stopgain mutations. c Number and
proportion of transition and transversion. d Number of base substitutions. e Number of somatic mutations in a tumor patient. f Average number
of somatic mutations in carcinoma and sarcoma. g Average number of somatic mutations per patient across 26 tumor types. h Mutation
densities (mutation number in a region/region bp length) in coding regions and non-coding regions. i Number of the top 10 recurrent mutations.
Mean ± SEM, t test was used
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significantly lower than those in carcinomas (Fig. 1e, right).
The mutation levels, available for 2962 mutations, ranged
from 2% heteroplasmy to 100% homoplasmy. Of the
5920 somatic mutations, more than half (2951,
51.10%) were not registered in the mitomap database
updated on 29 Dec 2016 [25].
The relaxation of negative selection on tumor somatic
mtDNA Single Base mutations

To evaluate the effects of natural selection on single base
mutations, mutation patterns were analyzed in general
population, tumor, and simulation data. Compared with
general population data, tumor data showed a higher
proportion of nonsynonymous mutations in mRNA-coding
regions, more deleterious mutations in tRNA coding
regions, higher impact on protein function, and more
codons that cannot be completely complementary with anticodon (Fig. 2a-d, left panel). These phenomena were considered as a result of positive selection in previous studies [17].
Alternatively, another plausible model has been suggested
that these tumor mutation patterns were shaped by mutation rate bias and relaxation of negative selection [13, 17].
To further investigate whether the observed mutation
patterns in the datasets that we developed are consistent
with the relaxation of selection, we generated simulation
data of mtDNA mutations under neutrality based on the
mutation rate bias shown in Fig. 1b (see Methods). No
significant differences existed between the observed mutations and the simulated data, supporting the effects of the
relaxation of selection on mtDNA mutations at the genome
scale (left panel of Fig. 2 a-d).
To rule out the possibility that mutations with different
heteroplasmic levels are under different selective constraints, we stratified the analyses by heteroplasmic levels
(≤0.05, 0.05–0.9, ≥0.9) and found that the same conclusion
holds regardless of the heteroplasmy levels (Fig. 2 a-d,
middle panel). Furthermore, we found that heteroplasmic
levels were not significantly different between synonymous and nonsynonymous mutations, between deleterious
and benign mutations in tRNA coding regions, among
mutations with different damage grades in mRNA coding
regions, and among mutations resulting in different codon
substitutions (Fig. 2a-d, right panel). Taken together, our
results indicate that single base mutations at the genome
scale are not restricted by natural selection, which is
consistent with previous reports [17, 18].
Functional unit-specific selection on tumor somatic
mtDNA mutation

Previous studies demonstrated strong negative selection
on truncating mtDNA mutations and tRNA anticodons
[17, 18]. To further explore the effects of functional
unit-specific natural selection on tumor mtDNA mutations, we compared the mutation rate (mutation number
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in a region/region bp length) in different mtDNA coding
regions. Interestingly, we found that the mutation densities in complex V and tRNA coding regions were
significantly lower than those in other regions (p < 0.0001,
Fig. 3a). Considering the different mutation rates of 4 bases
(Fig. 1b), the stratified analyses were performed. Our results
indicated that the mutation rates of complex V and tRNA
coding regions were the lowest among 6 subgroups when
stratified by A, G and T bases (Fig. 3b). We further explored
the mutation densities within the complex V and tRNA
regions and found that ATP8 has a lower mutation density
than ATP6 in complex V region (p = 0.0053, Fig. 3c). The
mutation densities in the loop/variable regions in tRNA
were significantly lower than those in the stem regions
(p = 0.0005, Fig. 3d, middle and right panels).
Site-preferred recurrence of tumor somatic mtDNA
mutations

A total of 5920 mutations occurred at 3590 distinct positions, among which 2384 were singletons and 3536 (59.73%)
were recurrent. The recurrent mutations can be collapsed
onto 1206 mtDNA positions with recurrence rate (i.e., number of patients carrying the same mutation) ranging from 2
to 28. The 10 most recurrent mutation positions were listed
in Fig. 4a. Furthermore, we found that non-coding regions
had a higher probability of recurrent mutations than coding
regions (p < 0.0001, Fig. 4b). The proportion of nonsynonymous mutations was higher in recurrent mutations than in
singletons (p < 0.0001, Fig. 4c). The heteroplasmic levels of
recurrent mutations tend to be higher than those of
singletons, although the differences were not significant
(p = 0.0611, Fig. 4d). These findings indicate that the recurrence of tumor somatic mtDNA mutations is site-preferred,
especially in non-coding region, and suggested the presence
of positive selection of mtDNA mutations in tumors.
Codon-specific selection on tumor somatic mtDNA
mutations

Given that codons are the most fundamental units for protein coding, we are interested in learning whether specific
mutation-caused codons are favorably or unfavorably
selected. To this end, the number of each codon generated
by base mutation from simulated data was analyzed and
compared with that from the observed data. As expected,
the results from simulated and observed data were highly
correlated (r = 0.9249, p < 0.0001, Fig. 5a), also indicating
that the overall codon mutations are shaped by the relaxation of negative selection. However, several specific codon
mutations significantly deviated from the trend line (i.e.,
above or below) by more than 2 standardized residuals.
Among them, the observed numbers of mutant codon
CCC (Pro) and ACC (Thr) were significantly higher than
the simulated values (standardized residuals of 3.58 and
2.79, respectively), suggesting that positive selection might
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Fig. 2 The relaxation of negative selection on majority of tumor somatic mtDNA single base mutations. a, b, c, d Proportion of synonymous and
nonsynonymous single base mutations in mRNA-coding regions, benign and deleterious in tRNA coding regions, mutations with different damage grades in
mRNA coding regions, those resulting in different codon substitutions in population, tumor and simulation data (Left); Proportion only in tumor data stratified
by heteroplasmic levels (Middle); Average heteroplasmic level in tumor data (Right). CC: codons completely complementary to anti-codons. NCC: codons not
completely complementary to anti-codons. Left and middle: chi-square test was used. Right (a, b): t test was used; Right (c, d): ANOVA was used

act on these specific mutant codons. In contrast, the
observed numbers of mutant codon GAC (Asp) and AGC
(Ser) were significantly lower than the simulated values
(standardized residuals of −2.37 and −2.85, respectively),
implying the possibility of negative selection of these

mutant codons (Fig. 5a, b). To investigate the robustness of
the analysis, we carried out the same simulation 10 times
and observed consistent patterns in all simulations (data
not shown). To exclude the possibility that the outliers were
influenced by the local sequence context of mutations, we

Fig. 3 Functional unit-specific selection on tumor somatic mtDNA mutations in coding regions. a Mutation densities (mutation number in a region/region
bp length) in different coding regions. b Mutation densities of T, C, A, G bases in different coding regions. c Mutation densities in ATP6 and ATP8 genes. d
Mutation densities in functional units of tRNA coding regions. tRNA functional units were shown (Left). Chi-square test was used
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Fig. 4 Site-preferred recurrence of tumor somatic mtDNA mutations. a Recurrent times of top 10 mtDNA Positions. b Recurrent mutation rate,
which was defined as the total recurrent times of mutations divided by bp length of region, in non-coding and coding regions. Chi-square test
was used. c The proportion of nonsynonymous and synonymous mutations in recurrent mutations and singletons. d The heteroplasmic level of
recurrent mutations and singletons

Fig. 5 Codon-specific selection on tumor somatic mtDNA mutations. a The correlation between numbers of mutation-caused codon from observed and
simulated data. Red circles showed 4 codons which were significantly deviated from trend line. b Residuals and standardized residuals of four outliers in (a)
were shown. c Heteroplasmic level of mutation-caused codons. Mean ± SEM, t test was used
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re-analyzed the site-specific selection by examining the
bases immediately 5′ and 3′ to the mutated bases. As
shown in Additional file 1: Figure S3, significant correlation between observed and simulated mutant tripletbases was observed (r = 0.9836, P < 0.0001). Moreover,
three triplet-bases CAC, CAA and GAC with above −2 or
2 of standardized residuals were identified, suggesting that
local sequence context may contribute to evolutional
selection of specific mutations, although the underlying
mechanism is largely unknown. Further analysis indicated
that these three triplet-bases were not related with the
selected codons shown in Fig. 5a. Specially, triplet-bases
GAC in Additional file 1: Figure S3 and codon GAC in
Fig. 5a were located on the different sides of trendline.
Our results suggest that the outliers in Fig. 5a may not be
determined by the context sequence. In addition, we also
found that the average heteroplasmic levels of the base
mutations in codon CCC and ACC were significantly
higher than those in codon GAC and AGC (p = 0.0423,
Fig. 5c), further supporting the existence of codon-specific
selection on tumor mtDNA mutations.
Amino acid-specific selection on tumor somatic mtDNA
mutations

We further investigated the site-specific selection of
mtDNA mutations at the amino acid level. Similarly, the
number of each amino acid generated by mutant codons
from observed or simulated data was determined. Once
again, we found that the value from the simulated data
was highly correlated with that from the observed data
(r = 0.9533, p < 0.0001, Fig. 6a), further confirming the
relaxation of negative selection for overall mutations.
Nevertheless, the mutant amino acid Thr was significantly above the trend line (standardized residual of
2.21) and Ter (terminator) was significantly below the
trend line (standardized residual of −2.05) (Fig. 6b). In
addition, both amino acids Pro and Ser were also above
and below trend line, respectively, although the deviations were not significant (standardized residuals of 1.23
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and −0.89, respectively). We also observed that the average heteroplasmic level of the base mutations in amino
acids Thr was significantly higher than that in Ter (p =
0.012, Fig. 6c), which supports the notion that mutant
amino acids are under specific selection. Notably, these
findings align well with the selection pattern of codon
mutations shown in Fig. 5.
Functionality of tumor somatic mtDNA mutations under
site-specific selection

We investigated the predicted functionality of mutations in
different genome regions and found that the proportion of
mutations predicted to be highly deleterious was significantly
different among complex III, IV, I, and V coding regions with
the lowest value in complex V (p < 0.0001, Fig. 7a), suggesting the stricter negative selection on complex V, especially in
ATP8 (p < 0.0001, Fig. 7b). We also observed that the proportions of deleterious mutations in loop and variable regions were significantly lower than those in stem regions (p
< 0.0001, Fig. 7c), indicating the possibility of stricter negative
selection on loop and variable regions of tRNA. Moreover,
we observed that the proportions of deleterious mutations in
CCC and ACC codons and threonine were significantly
greater than those in GAC and AGC codons and terminator, respectively (both p < 0.0001, Fig. 7d and e).

Discussion
Somatic mtDNA mutations have attracted significant attention because of their high frequencies in cancers [3, 4]. Specific mtDNA mutations have been implicated in tumor
development and metastasis [5, 6]. However, an increasing
number of recent studies have shown that tumor mtDNA
mutations are under relaxed negative selection [13, 17, 18].
While the differing findings of these studies has raised controversy over the existence of specific functional mtDNA
mutations, the indications of the relaxation of negative selection on the majority of tumor mtDNA mutations does not
completely exclude the possibility of site-specific selection
on individual mutations. To resolve these controversies, we

Fig. 6 Amino acid-specific selection on tumor somatic mtDNA mutations. a The correlation between the number of mutation-caused amino acid
from observed and simulated data. Red circles showed the mutation-caused threonine and terminator deviated from trend line. b Two outliers in
(a). Standardized residuals indicate threonine and terminator are selected. c Heteroplasmic level of mutation-caused threonine and Terminator.
Mean ± SEM, t test was used
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Fig. 7 Functionality of tumor somatic mtDNA mutations under site-specific selection. a Proportion of mutations with high and medium impact in different
coding regions. b Proportion of mutations with high impact in ATP6 and ATP8 coding regions. c Proportion of deleterious mutations in stem or loop and
variable regions of tRNA. d Proportion of mutations with high impact in mutation-caused codons with significant positive and negative selection. e Proportion
of mutations with high impact in mutation-caused threonine and terminator. Chi-square test was used

developed a comprehensive dataset of tumor mtDNA mutations and systemically analyzed the effects of site-specific
selection on these mutations. We found most tumor
mtDNA mutations are under the relaxed negative selection,
which is highly consistent with previous studies [13, 17, 18].
We also noted that some specific regions are under stricter
negative selection than other regions.
We further found that mutations in tRNA and complex
V coding regions showed evidence of negative selection,
especially in ATP8 gene coding regions of complex V and
loop and variable regions of tRNA. In line with our
findings, a previous study reported that ATP8 gene seems
to be protected from the relaxation of negative selection
[26, 27]. Moreover, we found that the selective pattern on a
region is related with the deleterious risk of mutations. This
finding further confirms the fact that mutations in complex
V and tRNA are under stricter negative selection, especially
in ATP8 of complex V and variable/loop regions of tRNA,
and partially explains the reason of evolutional constrains
on these regions. This evolutional constraint implies that

the mutations disrupting the normal function of complex V
and tRNA may confer an evolutionary disadvantage for
tumors that predispose tumor to being negatively selected.
Consistently, the important role of complex V in the
etiology of tumor is also supported by experimental mouse
data. For example, Petros et al. revealed that the prostate
cancer cells with mutation T8993G in ATP6 gene generated
larger tumor than wild-type cancer cells [28]. The essential
role of the electron transport chain in aspartate synthesis
[29] may be the reason that mtDNA mutations, especially
those deleterious mutations, are negatively selected. The
functional roles of mutations in complex V and tRNA in
tumor need in-depth future investigations.
Recurrent mutations were analysed in this study.
Generally, the recurrence of mutation in population
tends to be the evidence of positive selection [30], which
partially support our ratiocination. However, we cannot
rule out such a possibility of negative selection on
coding regions of mtDNA in tumors, which needs to be
further explored in future studies.

Li et al. Journal of Experimental & Clinical Cancer Research (2017) 36:168

Our study also identified the specific codons and amino
acids which tend to be under positive or negative selection.
Our findings from selected codons and amino acids further
supported the existence of site-specific selection of tumor
mtDNA mutations and demonstrated that some selected
mutations have potentially important functions in tumors.
Moreover, our finding that the mutation-caused terminator
was negatively selected is consistent with previous reports
[17, 18], further supporting the reliability of our findings.
Our analyses also showed that those codons that tend to be
positively selected have a significantly higher pathogenic
risk than those that tend to be negatively selected, and this
may be the reason why these mutations are differentially
selected. In consideration of the deleterious impact of stopgain mutations, the negative selection on stop-gain mutations enhanced the important role of mtDNA in tumors.
The positive selections of codon CCC and ACC and amino
acid Thr may imply the growth advantage they confer to
tumor cells and needs to be further explored in the future.
In addition to the functional impact of the mutations
in mRNA coding regions, the impacts on the mitochondrial pool of free amino acids may be one of the reasons
that some amino acids are differentially selected. Previous study suggests that the concentration of free amino
acids in mitochondria is positively correlated with the
composition of mtDNA-encoded proteins [31]. Therefore, the mutation-caused composition changes of amino
acids in mtDNA-encoded proteins may consume some
free amino acids and increase the concentration of other
free amino acids, which may influence the concentration
of free amino acids and cause the unbalance of free
amino acids pool in mitochondria. Considering the
important roles of the concentration of free amino acids
in tumor cells [29, 32–36], the changes in free amino
acid concentration in mitochondria may influence the
phenotype of tumor cells. This conjecture is supported
by the observation that the codons/amino acids identified to be selected in our study (Asp, Ser, Pro) overlap
with the amino acids that are reported to influence the
phenotype of tumor cells [34–36]. However, it is largely
unknown about the cause-effect relationship between
mtDNA mutation and the change of free amino acid
concentration. On one hand, it is possible that the state
of the amino acid pool may result in some codons/
amino acids to be selected for. On the other hand, the
impacts of mutation on the mitochondrial pool of free
amino acids may be one of the reasons that some amino
acids are differentially selected. Therefore, the relationship between the amino acid pool and mtDNA mutation
need to be further explored in future study.

Conclusions
Our results showed that the global landscape of tumor
mtDNA mutations is shaped by the relaxation of

Page 11 of 12

negative selection, and our detailed analysis also identified regions and functional units that are under sitespecific positive or negative selection, suggesting the
extensive involvement of natural selection on mtDNA
mutations during tumor development. The site-specific
selection of tumor mtDNA mutations provides clues to
identify driver mtDNA mutations of tumorigenesis and
progression. More tumor mtDNA sequencing data and
mechanistic experiments are needed to gain further insights into the roles of mtDNA mutations in tumors.
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